Relapse-Free Survival in Patients With Nonmetastatic, Surgically Resected Pancreatic Neuroendocrine Tumors

Strosberg, Jonathan R.; Cheema, Asima; Weber, Jill; Ghayouri, Masoumeh; Han, Gang; Hodul, Pamela J.; Kvols, Larry K.

doi:10.1097/sla.0b013e31824e6108

Cited by 136 publications

(61 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Late relapses have also been reported in other series and case reports, e.g. Strosberg et al [14] mentioned 35% late recurrences in their cohort of pancreatic NETs, Ciment et al [23] reported a case of recurrence 11 years after resection of a typical pulmonary carcinoid. The risk of recurrence at 5 years in the bias-corrected cohort was 28%.…”

Section: Discussionmentioning

confidence: 72%

“…The risk of recurrence at 5 years in the bias-corrected cohort was 28%. We and others [13,14] could demonstrate that the majority of recurrences (74%) are distant metastases, most often liver metastases.…”

Section: Discussionmentioning

confidence: 99%

“…Routine use of the proliferation marker Ki-67 was not established before the year 2000 and Ki-67 rates were not available in 24% of patients. Strosberg et al [14] have shown that stage by AJCC and by ENETS classification in a cohort of pancreatic patients is prognostic for RFS. These classifications were established in 2010 and 2006, respectively, and were not available in the majority of our patients.…”

Section: Discussionmentioning

confidence: 99%

“…Additional data exist for prognostic factors after surgery [6,12,13], but the analyses of risk factors for recurrent disease are limited. Recently, Strosberg et al [14] showed that staging of pancreatic NETs according to ENETS or AJCC is prognostic for recurrence. Two studies [15,16] identified Ki-67 >5% and a high lymph node ratio (LNR) as risk factors for recurrence in pancreatic NET patients.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Well-Differentiated Neuroendocrine Neoplasia: Relapse-Free Survival and Predictors of Recurrence after Curative Intended Resections

Dieckhoff¹,

Runkel²,

Daniel³

et al. 2014

Digestion

View full text Add to dashboard Cite

Background: Resection with curative intention is the cornerstone of treatment in patients with neuroendocrine tumors. A proportion of patients will relapse after R0 resection, but the factors predictive of recurrence are not well understood. Methods: A database established 1998 at the University Hospital Marburg was queried for all patients with documented R0 resection. Recurrence-free survival and overall survival were estimated using the Kaplan-Meier method. Uni- and multivariate analyses were performed. Results: 180 patients with a median age of 52 years entered the analysis. We observed 77 recurrences after a median time of 2.9 years. 24% of the recurrences occurred later than 5 years after operation. Median recurrence-free survival of the whole cohort was 101 months. In univariate analysis grade by Ki-67, stage, high lymph node ratio and microangioinvasion were significant predictors of recurrence. On multivariate analysis these parameters were confirmed as independent prognostic parameters with stage and microangioinvasion being the most important predictors. Conclusions: After R0 resection of neuroendocrine tumors, postoperative surveillance should be extended to at least 10 years. Patients with distant metastases and microangioinvasion are at high risk of recurrence. Clinical trials of adjuvant treatment protocols are indicated in these patients.

show abstract

Section: Discussionmentioning

confidence: 72%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Well-Differentiated Neuroendocrine Neoplasia: Relapse-Free Survival and Predictors of Recurrence after Curative Intended Resections

Dieckhoff¹,

Runkel²,

Daniel³

et al. 2014

Digestion

View full text Add to dashboard Cite

show abstract

“…To date, at least three formal staging systems have been proposed by three different major organizations, including the World Health Organization (WHO), the European Neuroendocrine Tumor (ENETS), and the American Joint Commission on Cancer (AJCC) [41][42][43]. Although each of these staging systems utilizes slightly different criteria, their ability to predict survival is quite similar [44][45][46].…”

Section: Stagingmentioning

confidence: 99%

Pancreatic Neuroendocrine Tumors: an Update

2015

View full text Add to dashboard Cite

Pancreatic neuroendocrine tumors (pNETs) are rare and comprise only 1-2 % of all pancreatic neoplastic disease. Although the majority of these tumors are sporadic (90 %), pNETs can arise in the setting of several different hereditary genetic syndromes, most commonly multiple endocrine neoplasia type 1 (MEN1). The presentation of pNETs varies widely, with over 60 % having malignant distant disease at the time of initial diagnosis involving the liver or other distant sites. Functioning pNETs represent approximately 10 % of all pNETs, secrete a variety of peptide hormones, and are responsible for several clinical syndromes caused by profound hormonal derangement. Surgery remains the cornerstone of therapy and the only curative approach. It should be pursued for localized disease and for metastatic lesions amenable to resection. Multimodality therapies, including liver-directed therapies and medical therapy, are gaining increasing favor in the treatment of advanced pNETs. Their utility is multifold and spans from ameliorating symptoms of hormonal excess (functional pNETs) to controlling the local and systemic disease burden (non-functional pNETs). The recent introduction of target molecular therapy has promising results especially for the treatment of progressive well-differentiated G1/G2 tumor. In this review, we summarize the current knowledge and give an update on recent advancements made in the therapeutic strategies for pNETs.

show abstract

Management of solid and cystic lesions of the pancreas

Fogelman

Wolff

2016

Laparoscopic Liver, Pancreas, and Biliary Surgery

View full text Add to dashboard Cite

Relapse-Free Survival in Patients With Nonmetastatic, Surgically Resected Pancreatic Neuroendocrine Tumors

Abstract: The AJCC and ENETS TNM classifications for pancreatic NETs are prognostic for recurrence-free survival and can be adopted in clinical practice.

Cited by 136 publications

References 12 publications

Well-Differentiated Neuroendocrine Neoplasia: Relapse-Free Survival and Predictors of Recurrence after Curative Intended Resections

Well-Differentiated Neuroendocrine Neoplasia: Relapse-Free Survival and Predictors of Recurrence after Curative Intended Resections

Pancreatic Neuroendocrine Tumors: an Update

Management of solid and cystic lesions of the pancreas

Contact Info

Product

Resources

About